ENDRA Life Sciences Inc
NDRA5.100USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.01MMarket Cap
0.00P/E TTM
More Details of ENDRA Life Sciences Inc Company
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
ENDRA Life Sciences Inc Info
Ticker SymbolNDRA
Company nameENDRA Life Sciences Inc
IPO dateJun 28, 2017
CEOTokman (Alexander Y)
Number of employees21
Security typeOrdinary Share
Fiscal year-endJun 28
Address3600 Green Ct Ste 350
CityANN ARBOR
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code48105
Phone17343350468
Websitehttps://www.endrainc.com/
Ticker SymbolNDRA
IPO dateJun 28, 2017
CEOTokman (Alexander Y)
Company Executives of ENDRA Life Sciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
70.81K
+1200.99%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
--
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-99.96%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
70.81K
+1200.99%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
--
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-99.96%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 22
Updated: Sat, Nov 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ATW Partners LLC
9.95%
Lipman (John Carter)
6.52%
DiGiandomenico (Anthony)
6.07%
DRW Securities, LLC
1.09%
Geode Capital Management, L.L.C.
0.44%
Other
75.93%
Shareholders
Shareholders
Proportion
ATW Partners LLC
9.95%
Lipman (John Carter)
6.52%
DiGiandomenico (Anthony)
6.07%
DRW Securities, LLC
1.09%
Geode Capital Management, L.L.C.
0.44%
Other
75.93%
Shareholder Types
Shareholders
Proportion
Individual Investor
12.60%
Private Equity
9.95%
Investment Advisor
1.34%
Investment Advisor/Hedge Fund
0.44%
Hedge Fund
0.02%
Other
75.66%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
24
12.65K
1.08%
+1.88K
2025Q2
34
22.09K
2.99%
+12.79K
2025Q1
37
5.94K
0.98%
+652.00
2024Q4
38
889.00
0.17%
-4.90K
2024Q3
39
6.39K
8.81%
+5.79K
2024Q2
39
2.03K
9.18%
+1.72K
2024Q1
33
352.00
9.94%
+101.00
2023Q4
35
276.00
9.44%
+68.00
2023Q3
37
286.00
9.99%
+78.00
2023Q2
39
314.00
10.85%
+151.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
DiGiandomenico (Anthony)
5.44K
0.72%
+5.38K
+9125.42%
Jun 11, 2025
Geode Capital Management, L.L.C.
5.13K
0.68%
+594.00
+13.09%
Aug 31, 2025
The Vanguard Group, Inc.
116.00
0.02%
--
--
Aug 31, 2025
UBS Financial Services, Inc.
4.70K
0.62%
+4.70K
--
Jun 30, 2025
Northwestern Mutual Capital, LLC
35.00
0%
+35.00
--
Jun 30, 2025
Thornton (Michael Milos)
20.00
0%
--
--
Mar 24, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Aug 16, 2024
Merger
50→1
Aug 16, 2024
Merger
50→1
Date
Type
Ratio
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Aug 16, 2024
Merger
50→1
Aug 16, 2024
Merger
50→1
Aug 16, 2024
Merger
50→1
Aug 16, 2024
Merger
50→1
Dec 06, 2022
Merger
20→1
Dec 06, 2022
Merger
20→1
View more
FAQs
Who are the top five shareholders of ENDRA Life Sciences Inc?
The top five shareholders of ENDRA Life Sciences Inc are:
DiGiandomenico (Anthony) holds 5.44K shares, accounting for 0.72% of the total shares.
Geode Capital Management, L.L.C. holds 5.13K shares, accounting for 0.68% of the total shares.
The Vanguard Group, Inc. holds 116.00 shares, accounting for 0.02% of the total shares.
UBS Financial Services, Inc. holds 4.70K shares, accounting for 0.62% of the total shares.
Northwestern Mutual Capital, LLC holds 35.00 shares, accounting for 0.00% of the total shares.
DiGiandomenico (Anthony) holds 5.44K shares, accounting for 0.72% of the total shares.
Geode Capital Management, L.L.C. holds 5.13K shares, accounting for 0.68% of the total shares.
The Vanguard Group, Inc. holds 116.00 shares, accounting for 0.02% of the total shares.
UBS Financial Services, Inc. holds 4.70K shares, accounting for 0.62% of the total shares.
Northwestern Mutual Capital, LLC holds 35.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of ENDRA Life Sciences Inc?
The top three shareholder types of ENDRA Life Sciences Inc are:
ATW Partners LLC
Lipman (John Carter)
DiGiandomenico (Anthony)
ATW Partners LLC
Lipman (John Carter)
DiGiandomenico (Anthony)
How many institutions hold shares of ENDRA Life Sciences Inc (NDRA)?
As of 2025Q3, 24 institutions hold shares of ENDRA Life Sciences Inc, with a combined market value of approximately 12.65K, accounting for 1.08% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.91%.
What is the biggest source of revenue for ENDRA Life Sciences Inc?
In --, the -- business generated the highest revenue for ENDRA Life Sciences Inc, amounting to -- and accounting for --% of total revenue.
